Medindia
Medindia LOGIN REGISTER
Advertisement

CDI Labs Expands HuProt™ - The Highest Content Human Proteome Microarray in the World

Thursday, May 25, 2017 General News
Advertisement
Proteomics company now producing glass slides printed with recombinant human proteins comprising 81% of the human proteome for high throughput analytics, contract research and hybridoma development services.
Advertisement

MAYAGUEZ, Puerto Rico and BALTIMORE, May 25, 2017 /PRNewswire/ -- CDI Laboratories, Inc. has announced that over 1,000 new recombinant proteins will be added to HuProt™ - its human proteome microarray. With 81% of the human proteome available in a powerful and economical analytical platform*, the Company greatly strengthens its position as a global leader in microarray production, content and application development.
Advertisement

HuProt microarrays can generate massive binding profiles in days - not months - and are used in:

  • Serum (biomarker) profiling- disease diagnosis, prognosis; cancer immunotherapy, vaccine development 
  • Protein binding assays- small molecule binding, DNA/RNA binding, enzyme binding specificity, etc.
  • Antibody specificity testing- assess cross-reactivity, identify highest quality research reagents
"We're excited to launch the next generation of HuProt at ASCO 2017 in Chicago on June 3. With each version - and this is v3.1 - we are adding new proteins with the ultimate goal of having the entire human proteome on a slide." said Scott Paschke, CDI VP of Marketing. "Further, the proteins added to the latest generation represent finer coverage of proteins involved in autoimmune-related toxicities and conditions, transcription factor binding, and signal transduction pathways."

In mid-2016, CDI purchased an Arrayjet Ultra Marathon II non-contact piezoelectric (ink jet) robotic printer for its microarray manufacture. This high-capacity state-of-the-art instrument offers significant performance advantages over contact print methods including significant reductions in lot-to-lot variability and inter-assay variability. 

*HuProt microarrays are available for purchase by labs with in-house microarray scanning capability. Alternatively, CDI's Discovery Services division offers contract assay design, research, bioinformatics and custom-configured microarray production on a per-project basis.

About CDI - A privately-owned biotechnology corporation, CDI focuses on protein- and antibody microarray design, production and custom assay services. CDI's flagship - HuProt™ - is the most comprehensive human proteome microarray in the industry, allowing thousands of protein interactions to be done in parallel. HuProt enables R&D of future therapeutic and diagnostic tools to proceed more rapidly and cost-effectively. CDI's Fast-MAb® hybridoma development service addresses the urgent need for monoclonal antibodies with unprecedented specificity for research, diagnostic or therapeutic targets. Fast-MAb antibodies are evaluated for specificity on the HuProt array. The Company exports products world-wide and is expanding its clientele base and its academic and industrial collaborations.

For more information, visit cdi-lab.com.   ASCO booth #22143

Media Contact:

Scott Paschke, Vice PresidentCDI Laboratories Inc518-534-2881 (direct)[email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cdi-labs-expands-huprot---the-highest-content-human-proteome-microarray-in-the-world-300463306.html

SOURCE CDI Laboratories

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close